Follow up for Patients With Thyroid Cancer Planed for Radioiodine Scan or Treatment
Overview
The prevalence of thyroid cancer has increased in recent decades. Patients with thyroid cancer need to choose between Thyrogen® injection and Eltroxin® withdrawal before radioiodine therapy or scan. This is a prospective, observational study, aiming to observe the difference of metabolic profiles between patients choose Thyrogen® injection and Eltroxin® withdrawal.
Study Type
- Study Type: Observational
- Study Design
- Time Perspective: Prospective
- Study Primary Completion Date: June 30, 2028
Detailed Description
1. Objective: To observe the difference between Thyogen® injection or Eltroxin® withdrawal on metabolic profile. 2. Background and method:: The prevalence of thyroid cancer has increased in recent decades. Patients with thyroid cancer need to choose between Thyrogen® injection and Eltroxin® withdrawal before radioiodine therapy or scan. This is a prospective, observational study, aiming to observe the difference of metabolic profiles between patients choose Thyrogen® injection and Eltroxin® withdrawal. Inclusion : Patient number: 500人 Inclusion criteria : 1. Patients with diagnosis of thyroid cancer。 2. Patients who need radioiodine therapy or scan。 Exclusion criteria: 1. Patients cannot cooperate with blood test.。 2. Patients cannot cooperate with radioiodine therapy。 Study design: Prospective, observational study。 Method: We will collect 20cc blood and 20 cc urine before and after radioiodine therapy during each visit (total 3 visits) and check lipid profiles, glucose profiles and inflammation markers. We will compare the difference between results of patients undergoing Thyrogen® injection and Eltroxin® withdrawal.
Interventions
- Radiation: radioiodine
- Patients with thyroid cancer need to choose between Thyrogen® injection and Eltroxin® withdrawal before radioiodine therapy or scan.
Clinical Trial Outcome Measures
Primary Measures
- Zung’s Self-reported depression scale
- Time Frame: 1 month
- Depression symtpoms
Secondary Measures
- Brain-derived neurotrophic factor
- Time Frame: 1 month
- BDNF
- orexin
- Time Frame: 1 month
- An associated factor for depression
- Body composition
- Time Frame: 1 months
- Fat component percentage to lean mass percentage ratio
- VCAM-1
- Time Frame: 1 months
- adhesion molecules
- CRP
- Time Frame: 1 months
- inflammation marker
- Metabolic syndrome
- Time Frame: 1 months
- The number of conponents for metabolic syndrome
Participating in This Clinical Trial
Inclusion Criteria
1. Patients with diagnosis of thyroid cancer。 2. Patients who need radioiodine therapy or scan。 Exclusion Criteria:
1. Patients cannot cooperate with blood test.。 2. Patients cannot cooperate with radioiodine therapy。
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: N/A
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Taichung Veterans General Hospital
- Provider of Information About this Clinical Study
- Sponsor
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.